ABVC BioPharma (NASDAQ:ABVC) Trading 1.5% Higher – Here’s What Happened

ABVC BioPharma, Inc. (NASDAQ:ABVC) shares shot up 1.5% during trading on Thursday . The company traded as high as $2.11 and last traded at $2.08. 50,801 shares traded hands during mid-day trading, an increase of 1% from the average session volume of 50,541 shares. The stock had previously closed at $2.05.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ABVC BioPharma in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has an average rating of “Sell”.

ABVC BioPharma Trading Up 1.5%

The stock has a market capitalization of $50.54 million, a P/E ratio of -10.40 and a beta of 0.21. The firm’s fifty day moving average is $2.33 and its 200-day moving average is $2.79.

ABVC BioPharma (NASDAQ:ABVC) last issued its quarterly earnings results on Friday, October 31st. The company reported ($0.05) earnings per share for the quarter. The company had revenue of $0.80 million for the quarter.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Citadel Advisors LLC acquired a new stake in ABVC BioPharma in the 3rd quarter valued at $48,000. Millennium Management LLC acquired a new stake in ABVC BioPharma in the 3rd quarter worth about $60,000. Finally, Geode Capital Management LLC grew its position in ABVC BioPharma by 5.8% during the second quarter. Geode Capital Management LLC now owns 110,499 shares of the company’s stock worth $246,000 after buying an additional 6,017 shares in the last quarter. 11.38% of the stock is currently owned by institutional investors.

About ABVC BioPharma

ABVC BioPharma is a clinical-stage biotechnology company focused on the discovery and development of novel vaccine and immunotherapy candidates for oncology and infectious diseases. The company leverages a proprietary peptide-based platform to identify and synthesize immunogenic epitopes, aiming to stimulate targeted immune responses against tumor-associated and pathogen-derived antigens.

The company’s pipeline includes active immunotherapy programs designed to address a range of cancer indications, along with vaccine candidates targeting bacterial pathogens.